Quantcast
Last updated on April 18, 2014 at 0:07 EDT

Latest Ketones Stories

2014-02-04 12:26:39

The Quest Diagnostics Health Trends(TM) study of 2.7 million test results is the largest to examine warfarin treatment in patients with atrial fibrillation (Afib) treated in primary care and other non-hospital care settings in the United States MADISON, N.J., Feb. 4, 2014 /PRNewswire/ -- Approximately one in two patients with atrial fibrillation (Afib) do not optimally reduce their risk of stroke or bleeding when treated with the most widely prescribed oral-anticoagulant therapy,...

2014-02-03 20:22:33

WASHINGTON, Feb. 3, 2014 /PRNewswire-USNewswire/ -- A recent analysis, released by Trust for America's Health (TFAH) in October, of state drug laws and policies found a majority of states do not have laws that can provide help to individuals during an overdose. (Logo: http://photos.prnewswire.com/prnh/20100204/TFAHLOGO) -- Good Samaritan Laws: Only 17 states and Washington, D.C. have laws in place to provide a degree of immunity from criminal charges or mitigation of...

2014-01-30 08:30:48

First presentation of detailed BUNAVAIL clinical data scheduled for April 11 and 13, 2014 RALEIGH, N.C., Jan. 30, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) today announced that data from clinical studies of BUNAVAIL have been accepted for presentation at the American Society of Addiction Medicine (ASAM) 45(th) Annual Medical-Scientific Conference, April 10-13, 2014 in Orlando, Florida. (Logo:...

2014-01-29 16:29:05

DUBLIN, January 29, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/bgdzzw/tesaros) has announced the addition of the "Tesaro's Rolapitant: Competition for Emend" [http://www.researchandmarkets.com/research/bgdzzw/tesaros ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Tesaro's rolapitant is a NK-1 inhibitor in phase III trials for the prophylaxis of chemotherapy-induced nausea and...

2014-01-29 12:28:05

NEW YORK, Jan. 29, 2014 /PRNewswire/ -- Fresh Start Private Management, Inc. (OTCQB: CEYY) is an alcohol treatment and rehabilitation company on the leading edge of alcohol addiction treatment. The company has developed a highly effective program consisting of two components used by alcohol addiction clinics in the US. Clinic reports show that the treatment program has an 85% success rate with individuals that complete the program. The first component of the program consists of an outpatient...

2014-01-29 08:22:46

ALBANY, New York, January 29, 2014 /PRNewswire/ -- Transparency Market Research has released a new market report titled "Methyl Ethyl Ketone Market for Paints & Coatings, Printing Inks and Other Applications - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" which observes that the revenue generated by MEK (methyl ethyl ketone) market was USD 2,254.1 million in 2012 and is expected to reach USD 3,064.5 million by 2019, growing at a CAGR of...

2014-01-28 23:29:46

Passages Malibu CEO issues statement on the FDA Approval of Zohydro. Malibu, CA (PRWEB) January 28, 2014 The Food and Drug Administration (FDA) recently approved the sale of Zohydro ER, an extended release version of hydrocodone developed and manufactured by Zogenix. Following that approval, on December 12th 2013, attorneys general from 27 states and the US territory of Guam issued a letter, asking the FDA to reconsider its green light of the drug. A panel hired by the FDA voted 11-2...

2014-01-28 23:03:52

As Morgan & Morgan continues to investigate potential claims on behalf of Tylenol users, the firm is alerting consumers to reports that the FDA has recommended that doctors stop prescribing products with more than 325 mg of acetaminophen per dose. Tampa, FL (PRWEB) January 28, 2014 Morgan & Morgan continues to investigate lawsuits on behalf of Tylenol* users who suffered liver failure, as the FDA announces new recommendations for prescription drugs containing acetaminophen,...

2014-01-27 13:40:43

Researchers from Warwick Medical School have discovered a critical point of failure in the microscopic transport system that operates inside every cell in the human body. The study, published today in Nature Communications, explains how this tiny 'railway' system is a key target for cancer drugs and, as such, how this new discovery reveals how better drugs might be made. The tracks of this so called 'railway' are tiny tubes, called microtubules, 1000 times thinner than a human hair. The...

2014-01-23 20:22:19

HARBIN, China, Jan. 23, 2014 /PRNewswire/ -- Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company") (OTCQB: YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine and products made from yew timber in China, today issued the following letter to shareholders: DEAR FELLOW SHAREHOLDERS: With the arrival of the Chinese New Year, I would like to take this opportunity to express my appreciation to all shareholders for the trust and...